Catalyst

Slingshot members are tracking this event:

Top line data from PROMISE 2, a Phase 3 study of Eptinezumab in 1,500 Chronic Migraine patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TEVA

100%
AMGN

100%
ALDR

100%

Additional Information

Management Comment The second pivotal trial PROMISE 2 commenced in November of 2016 and is evaluating the safety and efficacy of eptinezumab administered via infusion once every twelve weeks for six months in approximately 1050 patients with chronic migraine.

~ Earnings call 4q 2016
https://seekingalpha...
Slingshot Insights Explained
Related Keywords Eptinezumab, Promise 2, Chronic Migraine